

WORLD THERAGNOSTICS DAY CELEBRATING ¹⁷⁷Lu-PSMA THERAGNOSTICS IN PROSTATE CANCER 31 MARCH 2022 VIRTUAL


TIME: 13H00 CENTRAL EUROPEAN TIME (CET)

31 March 2022		
	WARMTH	
13:00-13:05	Welcome	Mike Sathekge – WARMTH President
13:05-13:25	VISION Trial in mCRPC	Prof Oliver Sartor - USA
13:25-13:45	"Life after VISION: Where to next?"	Prof Louise Emmett - AU
13.45-14:00	QA & Discussion	ALL

Prof Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990, when he finished a fellowship at the National Cancer Institute (NCI). He has published over 300 articles and book chapters and led multiple national and international clinical trials as principal investigator or co-principal investigator. In particular, he has helped to lead pivotal trials leading to FDA approval for samarium-153 EDTMP, radium-223, and cabazitaxel. He has lectured widely and, at last count, has given invited lectures in 28 countries. Now recently for 177Lu-PSMA in Prostate cancer – Lead author of the Vision trial in NEJM.

He is currently the Assistant Dean for Oncology at Tulane University School of Medicine, Medical Director of the Tulane Cancer Center, and the Laborde Professor for Cancer Research, with appointments in the Medicine and Urology Departments.

He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is currently Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer and is the Medical Oncology Chair of the GU committee of NRG. He is also currently a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology).



Prof Louise Emmett is the Director of Theranostics and Nuclear medicine at St Vincent's Hospital Sydney, Australia with a specialty interest in the imaging and therapy of prostate Cancer. She undertook her medical undergraduate training in Auckland, New Zealand, prior to completing her specialty training in Nuclear Medicine in Sydney, and a post specialty Nuclear Cardiology fellowship in Toronto, Canada. She commenced work in Nuclear medicine and PET at St Vincent's Hospital, Sydney in 2012, initiating radio-pharmacy production of multiple new imaging and therapy peptides on the St Vincent's campus for clinical and research evaluation. She is the principal investigator in multiple phase I-II trials including the PRIMARY trial (PSMA + MRI in prostate diagnosis), LuPIN trial (Phase I/II trial of Lu PSMA+ Idronoxil), ENZAp(phase II randomised trial of enza vs enza + Lu PSMA), in addition to running multiple phase I imaging trials in new theranostic agents.

She is heavily involved in multi-disciplinary prostate cancer research in Australia, including imaging and therapy.

